Dr. Eugenia Steingold
Chief Science Officer
Chief Science Officer, Co-Founder, brings over 20 years' experience in autism research, diagnosis, and treatment. A licensed psychologist in NYS, she earned her PhD from Princeton University in psycholinguistics and cognitive psychology, and completed a postdoctoral fellowship at Harvard University in cognitive and linguistic development.
United States
Healthcare
Autism is a serious developmental disease that lasts a lifetime. The rates of autism continue to rise, the cause of the disease remains unknown and there is no cure. We believe that children on the autism spectrum can lead fulfilling and productive lives. That is why JelikaLite is developing Cognilum, an integrative solution with focus on pediatric neurological health using non-invasive novel therapies.
Cognilum will enable children to integrate into society, parents to receive a home-based personalized cost-effective treatment while having a better quality of life, therapists to track progress and efficacy of existing interventions, and both payors and government to spend less money on special education and lifelong residential care.
Cognilum may provide benefits that may be difficult to measure with money alone, yet society will bear the ultimate expenses if nothing continues to be done about the millions of children with autism and other neurological disorders who are unable to integrate into society.
Cognilum will enable children to integrate into society, parents to receive a home-based personalized cost-effective treatment while having a better quality of life, therapists to track progress and efficacy of existing interventions, and both payors and government to spend less money on special education and lifelong residential care.
Cognilum may provide benefits that may be difficult to measure with money alone, yet society will bear the ultimate expenses if nothing continues to be done about the millions of children with autism and other neurological disorders who are unable to integrate into society.
